AIM ImmunoTech (AIM) investor relations material

Executive summary

• The annual meeting will be held virtually on November 17, 2026, with voting on director elections, auditor ratification, and executive compensation.

• Stockholders of record as of September 28, 2026, are eligible to vote, with materials distributed starting October 8, 2026.

• The Board recommends voting for all five director nominees, the ratification of BDO USA, P.C. as auditor, and approval of executive compensation.

• The company emphasizes stockholder engagement and the importance of voting, regardless of share count.

• Forward-looking statements are included, with caution regarding risks and uncertainties.

Voting matters and shareholder proposals

• Proposal 1: Elect five directors to serve until the 2027 annual meeting.

• Proposal 2: Ratify, on a non-binding advisory basis, the selection of BDO USA, P.C. as independent auditor for 2026.

• Proposal 3: Approve, on a non-binding advisory basis, the compensation of named executive officers.

• Board unanimously recommends voting “FOR” all proposals.

• Deadlines for 2027 shareholder proposals and director nominations are specified, with compliance to SEC rules and bylaws required.

Board of directors and corporate governance

• Board consists of five nominees: Nancy K. Bryan, David I. Chemerow, Thomas K. Equels, Ted D. Kellner, and William M. Mitchell.

• Four directors are independent; the CEO is not independent.

• Board committees include Audit, Compensation, Corporate Governance and Nomination, and Executive Committees.

• Board and committees met regularly in 2025, with high attendance.

• Code of Ethics applies to all directors, officers, employees, agents, and consultants.

• Board leadership structure separates Chair and CEO roles.